• BioDlink has been awarded the title of “Emerging CDMO of the Year” in recognition of its innovative work in complex biologics and ADC development.
• This award acknowledges the company’s proprietary technology platforms, scalable manufacturing capabilities, and a robust, proven quality system that has successfully passed over 100 audits.

SUZHOU, China, March 13, 2026 — BioDlink, an innovation-focused Contract Development and Manufacturing Organization (CDMO), revealed today that it has received the “Emerging CDMO of the Year” honor at the Asia-Pacific Biopharma Excellence Awards, hosted by IMAPAC.

Hosted by IMAPAC, the Asia-Pacific Biopharma Excellence Awards celebrate excellence and innovation across the biopharmaceutical sector in the Asia-Pacific region. These awards recognize organizations that exhibit exceptional technological prowess, operational excellence, and leadership in advancing biopharma development and manufacturing. By honoring these achievements, the program highlights companies shaping the future of the global biopharma ecosystem.

This recognition underscores BioDlink’s growing status as a trusted development and manufacturing partner for global biopharmaceutical innovators. The company delivers integrated solutions for complex biologics and antibody-drug conjugates (ADCs), supporting projects from early research and technology assessment through process development, analytical development, and manufacturing.

BioDlink’s capabilities are backed by a suite of proprietary technology platforms designed to boost development efficiency and scalability. These include GL-DisacLink^®, a co-developed conjugation platform that simplifies ADC manufacturing via a streamlined enzyme-based strategy; BDKcell, a cell line development platform delivering high-expression performance in standard fed-batch processes across multiple biologic modalities (monoclonal antibodies, bispecific antibodies, fusion proteins, and nanobodies); and BDKLyo, a digital-intelligent lyophilization process calculation platform that uses predictive modeling to accelerate development and enable efficient scale-up, helping partners reach critical production milestones faster and with greater confidence.

Complementing its technology platforms, BioDlink continues to expand its development and manufacturing infrastructure to support global programs across various stages. The company offers scalable production capabilities for complex biologics, enabling smooth progression from early development to manufacturing while maintaining consistent quality standards.

Quality remains a core focus of BioDlink’s operations. The company operates under a robust quality management system aligned with international regulatory expectations, boasting a successful track record of over 100 client and regulatory audits—supporting reliable development, manufacturing consistency, and regulatory readiness for global programs.

As global demand for advanced biologics and antibody-drug conjugates grows, BioDlink remains committed to strengthening its technology platforms, expanding manufacturing capabilities, and deepening collaborations with partners across the global biopharmaceutical ecosystem to bring innovative therapies to patients faster.

About BioDlink Biopharm Co., Ltd.

BioDlink (1875.HK) is a leading global CDMO specializing in biologics and bioconjugates (ADCs/XDCs). Headquartered in Suzhou with centers in Shanghai and Beijing, the company provides fully integrated, end-to-end services spanning early R&D to commercial manufacturing.

Leveraging its unified integrated platform and proprietary technologies—such as BDKcell® for rapid cell line development and GL-DisacLink® for site-specific conjugation—BioDlink helps partners accelerate development, improve efficiency, and reduce costs.

The company operates four commercial manufacturing lines with large-scale sterile fill-finish capabilities, backed by a global GMP-aligned quality system that has earned PMDA accreditation in Japan and supported product approvals across China, Indonesia, Nigeria, Pakistan, Colombia and Bolivia.

Guided by the philosophy of “Quality First, Innovation Driven, Success Together,” BioDlink is committed to advancing global access to next-generation biologics and building trusted partnerships worldwide.

For more information, please visit: https://www.biodlink.com/

 

SOURCE BioDlink Biopharm Co., Ltd.